BCWORLD PHARM. Co., Ltd. Overview
BCWorld Pharm is a small, owner-controlled Korean specialty-generic pharmaceutical manufacturer focused on hospital injectables. Its main areas are carbapenem antibiotics, anesthesia and narcotic analgesics, and cardiovascular agents. It is increasingly using drug-delivery-system (DDS) formulation technology to differentiate generics. FY2025 revenue was KRW 75.8 bn, and more than 90% of sales are domestic. The company owns two GMP manufacturing sites: Yeoju, and Wonju (operated by subsidiary BCWorld Healthcare). The Wonju site includes a dedicated penem facility. The company also runs CMO/CDMO services and a direct sales force. Its stated strategy rests on two formulation platforms. The first is orally disintegrating tablets (ODTs), with three launched to date: rosuvastatin, telmisartan and amlodipine. The second is long-acting injectables (LAIs), currently preclinical. It also in-licenses specialty brands such as Grünenthal's Nucynta. Management targets KRW 200 bn revenue by 2028, but the business has grown at only about 5% a year since 2021. It carries KRW 86 bn of mostly short-term debt and trades at roughly 0.45x book value.
What the company does. BCWorld Pharm researches, develops, manufactures and sells prescription (ethical) pharmaceuticals. In its investor presentations it calls itself a "fully integrated value chain enterprise" covering R&D, production (own products plus contract manufacturing), and sales [IR-2024-10]. Since 2024 its IR materials have carried the tagline "DDS-technology-specialized innovative pharmaceutical company leading global market entry" [IR-2024-10], [IR-2025-12].
Company's own description (paraphrased from IR, Oct 2024 and Dec 2025). The company sorts its business into four product groups: antibiotics, anesthesia/pain, cardiovascular, and others. It describes its products in three tiers. "Leading products" include the Mepem (meropenem) injection range, made in a dedicated plant, and BC Morphine Sulfate, which it says holds the No. 1 market share. "Differentiated products" include Supental (sufentanil), described as an original product. "Improvement products" are formulation-improved versions such as Suvaro OD (Korea's first statin ODT), the Tubis tuberculosis combination tablets (first domestic TB fixed-dose combination), and the Jext prefilled pen for anaphylaxis [IR-2024-10], [IR-2025-12]. The company also offers CDMO services covering raw-material sourcing, development, process, clinical and commercialization. It has multiple dosage-form capabilities: lyophilized products, penem powder injections, liquid ampoule and vial injections, tablets, capsules, sublingual tablets and ODTs [IR-2024-10].
Business and revenue model.
Product sales (dominant): Own-manufactured branded generics and improved formulations are sold to hospitals and clinics through a direct sales force (five sales branches as of Sep 2024) [IR-2024-10]. The in-licensed products are Nucynta and Jext, and the subsidiary distributes a pediatric sialorrhea product.
Contract manufacturing (CMO/CDMO): Manufacturing for third parties at the Yeoju and Wonju plants [IR-2024-10]. CMO revenue is not separately disclosed in the sources reviewed.
Exports: Finished injectables are sold to distributors and partners, mainly in Southeast Asia. Exports were KRW 5.9 bn, or 7.8% of FY2025 revenue [VL].
Licensing income: Historically the company licensed out a microsphere DDS prostate-cancer product with a US supply contract (Sep 2015) [IR-2024-10]. Current licensing revenue is not publicly disclosed.
Subscription or service revenue: none identified.
Value-chain position. The company is a midstream finished-dosage manufacturer. It does not appear to produce APIs at scale, so raw materials are a key cost (raw materials were KRW 26.9 bn of FY2025 cost of sales [VL]). It sells downstream through hospitals, wholesalers and export partners.
Customer types and end-markets.
-
General and tertiary hospitals, through the injectables portfolio: anesthesiology, ICU and infectious disease.
-
Clinics and pharmacies, through oral chronic-disease drugs such as the ODT cardiovascular line.
-
Overseas distributors and pharmaceutical companies in Vietnam, the Philippines, Thailand, Indonesia, Uzbekistan and elsewhere [IR-2024-10].
-
Pharmaceutical companies buying CMO services.
Independent characterization. BCWorld is a sub-scale (about KRW 76 bn revenue) Korean hospital-injectable house with a niche in narcotic analgesics and carbapenems, which together have historically made up most of its sales. It has a credible, but so far commercially small, formulation-differentiation strategy in oral cardiovascular ODTs. The ODT play is mainly an economic response to Korea's tiered generic pricing system: by being first in a new dosage form, a product can be listed at the highest price for its ingredient instead of competing as the nth generic [DP-2026-04-23]. The LAI platform is the long-dated option value in the story. At present the business is constrained by heavy, short-dated bank debt, high fixed costs from two plants, and thin operating margins (2.6% in FY2025). Interest expense consistently exceeds operating income at the consolidated level.
Strategy
Stated corporate strategy (themes, paraphrased from IR and management statements)
-
"DDS technology-specialized innovative pharmaceutical company." The company plans to move from generics, to ODTs, to improved new drugs, to long-acting injectables and new drugs. Its four-stage roadmap is foundation, growth phase 1, growth phase 2 and leap, with "mid-sized pharma company" status targeted by 2028 [IR-2024-10], [IR-2025-12].
-
Formulation as the answer to generic commoditization. Management judges that price competition among same-ingredient generics cannot defend profitability. It aims to shift prescriber choice through ODT and LAI convenience and compliance, and then build from there into improved new drugs and new drugs [DP-2026-01].
-
Revenue target of KRW 200 bn by 2028. This was first stated in October 2024 and reiterated in January 2026 [DP-2024-10], [DP-2026-01]. The October 2024 IR showed an organic path of KRW 91.0 bn (2025F), 107.2 bn (2026F), 114.1 bn (2027F), 121.4 bn (2028F), 129.2 bn (2029F) and 137.4 bn (2030F). Inorganic and new-business upside was shown as reaching about KRW 200 bn [IR-2024-10].
-
Global expansion. The goal is to lift exports to 30% of revenue within three years (stated April 2025). Initiatives include Japan entry, CMO partnerships with global companies, and Canada, US and Latin America expansion [DP-2025-04].
-
2026 operating priorities (New Year address). These are timely launches of new products, cost innovation, automation of facilities and work processes, an AI and open-innovation-based R&D foundation, rebuilding the ERP system, and group synergy. For BCWorld Healthcare the priorities are launching the pediatric sialorrhea product and securing a beachhead for global carbapenem sales [MG-2026-01].
-
Corporate value-up plan (March 2026). The plan has three pillars: revenue growth through continuous R&D and new product launches; profitability through cost improvement and operational efficiency; and stable, sustainable dividends. It also covers cash-flow management through financial-structure improvement, with the LAI programs as the mid- to long-term growth base [DP-2026-08]. Trade press notes that the 2026 value-up disclosure wave was driven partly by eligibility requirements for a dividend-income tax incentive for high-dividend companies [MT-2026-03].
Initiatives in the last 24 months
| Date | Initiative | Type | Source |
|---|---|---|---|
| Jun 2024 | First IR in five years, aimed at stock-price support | Investor relations | [DP-2024-06] |
| Jul 2024 | Nucynta in-license (Grünenthal) | Portfolio / in-licensing | [DP-2024-10] |
| Sep 2024 | Expanding the domestic hospital sales focus into anesthesiology and orthopedics. Pursuing Brazil, Saudi Arabia and Europe. Phased repayment of current borrowings | Commercial / financial | [DS-2024-09] |
| Dec 2024 | Cash plus stock dividend. "Active dividend policy" commitment | Capital return | [DP-2024-12] |
| Apr 2025 | Two-pillar plan of new products and global expansion. 30% export-share target | Strategy | [DP-2025-04] |
| Jul 2025 | Company-wide "Works AI" automation | Digital transformation | [MPH-2025-07] |
| Dec 2025 | IR update. New LAI programs in obesity (GLP-1-based), CNS expansion, and osteoarthritis and opioid-use-disorder indications planned | R&D | [IR-2025-12] |
| Jan 2026 | AI-driven drug discovery collaboration with SNU (target discovery, hit discovery, lead optimization) | R&D / open innovation | [HK-2026-01] |
| Mar 2026 | Corporate value-up plan | Governance / capital return | [DP-2026-08] |
| 2,026 | New ERP rebuild, facility and work automation, cost innovation | Cost program | [MG-2026-01] |
ESG commitments: none quantified.
Quantified cost-program targets: not publicly disclosed.
Medium-term targets and guidance
| Target | Value | Date stated | Source |
|---|---|---|---|
| Revenue | KRW 200 bn by 2028 | Oct 2024. Reiterated Jan 2026 | [DP-2024-10], [DP-2026-01] |
| Export share of revenue | 30% within about three years | Apr 2025 | [DP-2025-04] |
| Organic revenue path (IR chart) | 2025F 91.0, 2026F 107.2, 2027F 114.1, 2028F 121.4 (KRW bn) | Oct 2024 | [IR-2024-10] |
Tracking against targets: FY2025 actual revenue was KRW 75.8 bn against an organic forecast of KRW 91.0 bn, a shortfall of 17%. TTM Jun-2026 revenue was KRW 80.3 bn against a 2026F of KRW 107.2 bn. The 2028 target implies about 38% CAGR from FY2025. That rate appears inconsistent with the delivered trajectory unless there are material inorganic additions or LAI partnerships.
Products & Services
Pricing models are not publicly disclosed for any product. Korean prescription products are reimbursed at prices set by the national health insurance system.
Antibiotics
| Product | Description / specifications | Target customer | Launch / status | Source |
|---|---|---|---|---|
| Mepem Inj. (meropenem) | Carbapenem antibiotic powder for injection in 500 mg, 1 g and 2 g. Made in a dedicated production plant. The 1 g high-strength version launched Sep 2010 | Hospitals (ICU, infectious disease). Also exported to Vietnam, the Philippines, Thailand and Mexico (tenders), with a Japanese (PMDA) registration via a partner and a Czech contract in progress | Since 2010. Flagship antibiotic | [IR-2024-10] |
| Vancomycin HCl Inj. | Glycopeptide antibiotic injection made at Yeoju | Hospitals. Registered and sold in Thailand | Thai sales started after registration (2024 IR) | [IR-2024-10] |
| Tubis / Tubis 2 tablets | Tuberculosis fixed-dose combinations, described as the first domestically developed TB combination. Designated a nationally essential TB medicine. Improves adherence | TB clinics and hospitals | Marketed | [IR-2024-10] |
| I2102 (pipeline) | Antifungal injection generic. Bioequivalence secured. Filing planned for 2026 | Hospitals. Domestic market about KRW 4.5 bn (2023) | Planned launch 2026 per Dec 2025 IR (slipped from 2025) | [IR-2025-12] |
Anesthesia / Pain (including narcotics)
| Product | Description / specifications | Target customer | Launch / status | Source |
|---|---|---|---|---|
| BC Morphine Sulfate | Narcotic analgesic in multiple forms and strengths (vials and ampoules). The company claims No. 1 market share | Hospitals (anesthesia, oncology, pain) | Marketed. Leading product | [IR-2024-10] |
| Supental Inj. (sufentanil) | Opioid used for anesthesia, analgesia and sedation. The company calls it an "original product" | Anesthesiology | Marketed | [IR-2024-10] |
| Nucynta IR / ER (tapentadol) | Grünenthal-originated centrally acting analgesic for moderate-to-severe pain. Exclusive Korean supply agreement signed Jul 2024. Marketing authorization transferred from Janssen Korea from Feb 2025. Annual sales about KRW 6–7 bn at signing, with a potential market of about KRW 20 bn | Hospitals and pain clinics | Supplied by BCWorld from 2025. The company says it completes coverage across ultra-short-, short- and long-acting opioids | [IR-2024-10], [DP-2024-10] |
| Narco sublingual tablet | Treatment for breakthrough cancer pain. First generic with a priority marketing right | Oncology | Marketed | [IR-2024-10] |
| Naloxone HCl Inj. | Opioid antagonist injection made at Yeoju | Hospitals. Brazil registration in progress | Marketed domestically | [IR-2024-10] |
| G2202 (pipeline) | Generic for neuropathic pain | Domestic market about KRW 3 bn | Planned 2031 | [IR-2025-12] |
Cardiovascular
| Product | Description / specifications | Target customer | Launch / status | Source |
|---|---|---|---|---|
| Suvaro OD (rosuvastatin ODT) | Korea's first statin ODT, for hyperlipidemia. Dissolves in the mouth without water | Clinics. Elderly and dysphagic patients | Marketed. First ODT platform product | [IR-2024-10], [MT-2026-04] |
| Telbaro OD (telmisartan ODT) | Korea's first telmisartan ODT, for hypertension. Approved Jan 2025 (pipeline code G1906; domestic market about KRW 63 bn in 2023) | Clinics | Approved Jan 2025, launched 2025. Second ODT product | [DP-2025-04], [IR-2025-12] |
| Ambaro OD (amlodipine besylate ODT) | First amlodipine ODT in Korea, in 5 mg and 10 mg. Uses the company's taste-masking technology | Clinics. Hypertensive patients with dysphagia | Approved 22 Apr 2026. Sales from Aug 2026. Third ODT product | [DP-2026-05], [DP-2026-08-04] |
| Terampin S tablet | Antihypertensive. First generic with a priority marketing right | Clinics | Marketed | [IR-2024-10] |
| Norepinephrine Bitartrate Inj. | Vasopressor injection made at Yeoju | Hospitals. Exported to the Philippines via a leading local partner | Marketed | [IR-2024-10] |
| Nicardipine HCl Inj. | Calcium channel blocker injection made at Yeoju | Hospitals. Exported to the Philippines | Marketed | [IR-2024-10] |
Other prescription / specialty
| Product | Description / specifications | Target customer | Launch / status | Source |
|---|---|---|---|---|
| Jext prefilled pen | Adrenaline auto-injector for anaphylaxis, from pediatric to adult use. Exclusive supply, described as Korea's only anaphylaxis treatment of its kind. The licensor is not named in IR | Hospitals, pediatrics, allergy | Exclusive supply 2022 to present | [IR-2024-10], [IR-2025-12] |
| Pediatric chronic severe sialorrhea treatment (glycopyrronium bromide) | Approved in Aug 2025 via data-submission pathway for reducing chronic severe drooling in children aged 3–18 with chronic neurological conditions. First approval of this indication in Korea | Pediatric neurology and rehabilitation | Approved Aug 2025 (BCWorld Healthcare). Launch targeted Mar 2026 | [MT-2025-08], [IR-2025-12], [MG-2026-01] |
| Severe iron-deficiency treatment (in-licensed) | Product details not disclosed | Hospitals | Launch planned 2026 | [IR-2025-12] |
| Urology drugs and medical devices | Contract-manufactured / consigned urology products for a niche-market strategy | Urologists | Status not disclosed | [IR-2024-10] |
Services
| Service | Description | Source |
|---|---|---|
| CMO / CDMO | One-stop service from material purchasing to finished-product testing. Covers raw-material sourcing, development, process, clinical and commercialization. Dosage forms include lyophilized products, penem injections, liquid ampoule/vial injections, tablets, capsules and ODTs. Discussions are under way with a company "D" (CDA stage) and with Canadian and Japanese partners | [IR-2024-10], [DP-2025-04] |
Financial Narrative
Income statement — 5-year core metrics
Sources: [Butler], [ETFs], [IR-2025-12]. Margins and growth are computed. FY2021 OP is shown as -1.8 per Butler and the Dec 2025 IR; the Oct 2024 IR and ETFshopping show -1.5. FY2022 net income was KRW 59.78 million [Butler].
Revenue CAGR FY2021–FY2025: about 5.1% a year (computed: 75.8 / 62.1 over 4 years). Ten-year context: revenue was KRW 41.4 bn in 2015 [DP-2021-02], giving a CAGR of about 6.2% for 2015–2025.
FY2025 detailed income statement and TTM
Full line-item detail (gross profit, EBITDA, pre-tax income, EPS) could only be verified for FY2025 and trailing periods.
Source: [VL] (trailing-twelve-month series derived from DART quarterly filings). There is an EPS discrepancy: Simply Wall St reports FY2025 EPS of KRW -527.51 [SWS]. This is consistent with the same KRW -4.9 bn owners' loss divided by a smaller, unadjusted share count before the 2025–2026 stock dividends.
Half-year comparison (consolidated, KRW bn).
Sources: H1-2024 from [DS-2024-09]. H1-2024 revenue is derived from the reported 63.8% cost-of-sales ratio (KRW 22.8 bn). H1-2025 and H1-2026 are from [DP-2026-08]. Finance costs for H1-2024 are not disclosed in the source ("n.d."), so that cell cannot be charted.
Commentary: trends, inflections and drivers.
Top line: Growth stalled after the 2022 jump of +17.1%. FY2024 declined slightly (-0.4%). The company attributed this to fewer patients treated during the 2024 dispute between doctors and the government, which reduced hospital procedure volumes [DP-2025-04]. FY2025 grew only 1.3% even though Nucynta began contributing. H1-2026 reaccelerated to +12.5%. Likely contributors are the ODT launches, a full period of Nucynta, and the subsidiary's specialty launches. The company has not provided a product-level bridge.
Gross margin: Gross margin is drifting down, from about 40.5% on a TTM basis to 38.0%. H1-2026 cost of sales grew 22.0% against revenue growth of 12.5%, pushing the cost ratio to about 62.5%. Trade press flagged this as the main challenge for H2-2026 [DP-2026-08]. Possible drivers are a mix shift toward in-licensed, lower-margin product (Nucynta purchased finished) and fixed-cost absorption at the plants. This is an analyst inference that the company has not confirmed.
Operating leverage: H1-2026 OP improvement came almost entirely from SG&A cuts (down KRW 0.9 bn, -6.2%) rather than gross profit, which was flat [DP-2026-08].
Below the line: Interest expense of about KRW 4.1–4.4 bn a year is larger than operating income in every period shown, so the company is loss-making at the pre-tax level. Positive income-tax expense despite pre-tax losses suggests the profitable subsidiary is taxed while parent-level losses do not generate full tax benefit (analyst inference).
Minority leakage: Owners' net loss (KRW -4.89 bn in FY2025) is materially worse than the consolidated loss (KRW -3.14 bn). That is because about KRW 1.75 bn of subsidiary profit is attributable to non-controlling holders [VL]. This structural point matters for equity holders of the listed parent.
Balance sheet
Source: [VL]. Computed fields are total debt, net debt, short-term share and working capital. Debt includes short-term borrowings, short-term bonds, the current portion of long-term debt and long-term borrowings. Lease and other financial liabilities are excluded except for H1-2026. In H1-2026, long-term borrowings were reported as zero and KRW 10.70 bn appears as "long-term financial liabilities", which is treated here as debt. Net debt equals total debt minus cash and short-term financial assets.
Corroborating data point (mid-2024). DealSite reported, from the H1-2024 filing, the following figures [DS-2024-09]:
-
Cash including short-term financial assets: about KRW 6.5 bn.
-
Short-term financial liabilities: KRW 75.4 bn. This comprised short-term borrowings of KRW 55.4 bn, current portion of long-term borrowings of KRW 6.1 bn, and convertible bonds of KRW 11.5 bn.
-
Borrowings dependence: 50.1%.
-
Current ratio: 51.5%.
-
Debt-to-equity (liabilities/equity): 134.1%.
DailyPharm separately reported that the net-debt-to-equity ratio had exceeded 100% for three consecutive years as of mid-2024 [DP-2024-06].
Commentary.
-
The balance sheet is capital-intensive: PP&E is about 67% of assets. It is funded by rolling short-term bank debt, with roughly 84–88% of interest-bearing debt due within one year. Working capital has been structurally negative by about KRW 40–44 bn for four years.
-
Net debt has been sticky at about KRW 79–86 bn. Modest repayments have come mainly through amortization of long-term debt and reductions in short-term debt, which were largely refinanced. FY2025 financing flows show KRW 30.2 bn of new short-term borrowing and KRW 12.0 bn of new long-term borrowing, against KRW 36.0 bn of short-term repayments, KRW 5.65 bn of current long-term repayments and KRW 2.67 bn of bond repayments [VL].
-
Owners' equity has eroded from KRW 81.6 bn (FY2023) to KRW 69.5 bn (H1-2026). The causes are continued net losses plus dividends.
-
Inventories rose sharply from KRW 14.8 bn (FY2024) to KRW 22.8 bn (H1-2026). Merchandise (purchased goods) rose from KRW 0.47 bn to KRW 3.23 bn by FY2025. This is consistent with in-licensed product stock-building for Nucynta and other launches (analyst inference).
Cash flow
H1-2024 operating cash flow was KRW 0.44 bn, compared with KRW 4.0 bn in H1-2023 [DS-2024-09].
Source: [VL]. FCF is computed. ValueLine's own "free cash flow" field shows KRW -1.97 bn for FY2025 under a broader definition that includes other investing outflows.
Commentary. Cash from operations of about KRW 5–7 bn is largely absorbed by cash interest of about KRW 3.3–3.8 bn and maintenance-level capex of about KRW 2.4–5.3 bn. The business therefore generates near-zero free cash flow before dividends. Capex is rising, with construction-in-progress additions of KRW 4.15 bn in TTM Jun-2026. Working capital, mainly inventory, consumed KRW 6.6 bn in FY2025.
Ratios
All ratios are computed from [VL] data. ValueLine itself reports ROE of -4.17% [VL]. TTM Jun-2026 ROE uses the Jun-2025 to Jun-2026 average, approximated by the Dec-2025 and Jun-2026 points. The receivables, inventory and payables used are as at the period end.
Multi-year ratio series (where verifiable).
Overall assessment. The financial profile is that of a levered, low-return manufacturer. EBITDA margins of about 13–14% are respectable, but they are consumed by depreciation of about KRW 7.6 bn a year and by interest of about KRW 4.2 bn. Consolidated net profitability requires either OP of at least about KRW 5 bn sustained (as achieved in FY2023 at KRW 6.4 bn) or deleveraging.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (%)
| Product group (% of revenue) | FY2023 | FY2024 | H1-2026 |
|---|---|---|---|
Antibiotics (%) | 28 | 37 | 33.2 |
Anesthesia / pain (%) | 21 | 19 | 17.9 |
Cardiovascular (%) | 15 | 15 | 15.4 |
Other prescription drugs (%) | 34 | 29 | 33.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansProduct Group Details
| Product group (KRW Bn) | H1-2026 |
|---|---|
Antibiotics | 13.6 |
Other prescription drugs | 13.6 |
Anesthesia / pain | 7.3 |
Cardiovascular (derived residual) | 6.3 |
Total | 40.8 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 62.1 | 72.7 | 75.1 | 74.8 | 75.8 |
Revenue growth (%) | 8.9 | 17.1 | 3.3 | -0.4 | 1.3 |
Operating income (KRW Bn) | -1.8 | 1.9 | 6.4 | 1.5 | 2.0 |
Operating margin (%) | -2.9 | 2.6 | 8.5 | 2.0 | 2.6 |
Net income, consolidated (KRW Bn) | -2.2 | 0.06 | 2.9 | -3.3 | -3.1 |
Net margin (%) | -3.5 | 0.1 | 3.9 | -4.4 | -4.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (TTM Jun-2025–TTM Jun-2026)
| Metric | TTM Jun-2025 | TTM Sep-2025 | FY2025 | TTM Mar-2026 | TTM Jun-2026 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 75.31 | 77.04 | 75.80 | 79.81 | 80.32 |
Cost of sales (KRW Bn) | 44.82 | 45.80 | 45.21 | 47.88 | 49.80 |
Gross profit (KRW Bn) | 30.49 | 31.23 | 30.58 | 31.92 | 30.52 |
Gross margin (%) | 40.5 | 40.5 | 40.3 | 40.0 | 38.0 |
SG&A (KRW Bn) | 27.06 | 27.99 | 28.58 | 27.43 | 27.70 |
R&D expense in SG&A (KRW Bn) | 7.96 | 8.66 | 8.99 | 9.41 | 9.39 |
Operating income (KRW Bn) | 3.42 | 3.24 | 1.99 | 4.49 | 2.82 |
EBITDA (KRW Bn) | 10.48 | 10.36 | 9.85 | 12.61 | 11.47 |
EBITDA margin (%) | 13.9 | 13.4 | 13.0 | 15.8 | 14.3 |
Interest expense (KRW Bn) | 4.44 | 4.28 | 4.23 | 4.11 | 4.14 |
Pre-tax income (KRW Bn) | -1.58 | -1.57 | -2.21 | 0.54 | -0.77 |
Income tax (KRW Bn) | 0.44 | 0.59 | 0.93 | 1.02 | 0.48 |
Net income, consolidated (KRW Bn) | -2.03 | -2.16 | -3.14 | -0.48 | -1.26 |
Net income attributable to NCI (KRW Bn) | 1.70 | 1.59 | 1.75 | 2.02 | 1.63 |
Net income attributable to owners (KRW Bn) | -3.74 | -3.76 | -4.89 | -2.51 | -2.89 |
EPS basic (KRW) | -351 | -353 | -459 | -235 | -272 |
Income Statement
| Metric | H1-2024 | H1-2025 | H1-2026 |
|---|---|---|---|
Revenue (KRW Bn) | 35.8 | 36.3 | 40.8 |
Cost of sales (KRW Bn) | 22.8 | 20.9 | 25.5 |
SG&A (KRW Bn) | 13.7 | 14.3 | 13.4 |
Operating income (KRW Bn) | -0.8 | 1.1 | 2.0 |
Finance costs (KRW Bn) | — | 2.9 | 2.4 |
Net income (KRW Bn) | -3.3 | -2.1 | -0.2 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | H1-2026 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 183.05 | 184.11 | 176.31 | 176.80 | 173.61 |
Cash and equivalents (KRW Bn) | 4.03 | 6.99 | 5.44 | 5.88 | 3.86 |
Short-term financial assets (KRW Bn) | 4.02 | 4.81 | 2.46 | 0.92 | 1.07 |
Trade receivables (KRW Bn) | 16.51 | 18.19 | 20.29 | 18.73 | 17.77 |
Inventories (KRW Bn) | 16.78 | 17.09 | 14.84 | 21.30 | 22.81 |
Current assets (KRW Bn) | 43.60 | 48.08 | 44.55 | 49.07 | 48.13 |
Property, plant and equipment (KRW Bn) | 130.11 | 125.62 | 120.98 | 117.85 | 116.51 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Intangible assets (KRW Bn) | 2.82 | 2.99 | 2.71 | 2.54 | 2.25 |
Short-term borrowings (KRW Bn) | 35.55 | 46.98 | 56.68 | 50.82 | 55.52 |
Short-term bonds (KRW Bn) | 10.50 | 11.23 | 11.92 | 9.52 | 9.94 |
Current portion of long-term debt (KRW Bn) | 26.81 | 21.43 | 5.65 | 11.91 | 10.16 |
Long-term borrowings (KRW Bn) | 21.17 | 11.57 | 13.91 | 14.00 | 10.70 |
Total interest-bearing debt (KRW Bn) | 94.03 | 91.21 | 88.16 | 86.25 | 86.32 |
Short-term share of debt (%) | 77.5 | 87.3 | 84.2 | 83.8 | 87.6 |
Net debt (KRW Bn) | 85.98 | 79.41 | 80.26 | 79.45 | 81.39 |
Current liabilities (KRW Bn) | 84.20 | 92.24 | 85.86 | 89.71 | 91.55 |
Working capital (KRW Bn) | -40.60 | -44.16 | -41.31 | -40.64 | -43.42 |
Total liabilities (KRW Bn) | 105.53 | 104.24 | 100.30 | 104.29 | 102.26 |
Equity attributable to owners (KRW Bn) | 79.55 | 81.64 | 76.66 | 71.28 | 69.53 |
Non-controlling interests (KRW Bn) | -2.03 | -1.77 | -0.65 | 1.22 | 1.80 |
Total equity (KRW Bn) | 77.52 | 79.86 | 76.01 | 72.50 | 71.34 |
Book value per share (KRW) | 7,459 | 7,655 | 7,188 | 6,683 | 6,520 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | TTM Jun-2025 | TTM Sep-2025 | FY2025 | TTM Mar-2026 | TTM Jun-2026 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 6.62 | 4.11 | 5.57 | 2.17 | 4.74 |
Capex, tangible (KRW Bn) | 2.39 | 3.49 | 3.98 | 4.85 | 5.31 |
Free cash flow, OCF minus capex (KRW Bn) | 4.23 | 0.62 | 1.59 | -2.68 | -0.57 |
Interest paid (KRW Bn) | 3.81 | 3.65 | 3.49 | 3.35 | 3.29 |
Dividends paid (KRW Bn) | 0.54 | 0.54 | 0.54 | 0.54 | 0.92 |
Share buybacks (KRW Bn) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Net financing cash flow (KRW Bn) | -4.79 | -0.29 | -2.91 | -0.77 | -1.29 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | TTM Jun-2026 |
|---|---|---|
ROE, consolidated NI / avg total equity (%) | -4.2 | -1.7 |
ROE, owners' NI / avg owners' equity (%) | -6.6 | -4.1 |
ROA (%) | -1.8 | -0.7 |
Pre-tax ROIC, OP / (equity + net debt) (%) | 1.3 | 1.9 |
Current ratio (x) | 0.55 | 0.53 |
Debt / equity (x) | 1.19 | 1.21 |
Net debt / equity (x) | 1.10 | 1.14 |
Net debt / EBITDA (x) | 8.1 | 7.1 |
Interest coverage, OP / interest (x) | 0.47 | 0.68 |
EBITDA / interest (x) | 2.33 | 2.77 |
Asset turnover (x) | 0.43 | 0.46 |
Days sales outstanding (days) | 90 | 81 |
Days inventory outstanding (days) | 172 | 167 |
Days payables outstanding (days) | 62 | 50 |
Cash conversion cycle (days) | 200 | 198 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Debt / equity (x) | 1.21 | 1.14 | 1.16 | 1.19 |
Net debt / equity (x) | 1.11 | 0.99 | 1.06 | 1.10 |
Liabilities / equity (%) | 136.1 | 130.5 | 132.0 | 143.9 |
Current ratio (x) | 0.52 | 0.52 | 0.52 | 0.55 |
Revenue by Region and Revenue by Region (%)
| Region (KRW Bn) | TTM Jun-2025 | TTM Sep-2025 | FY2025 | TTM Mar-2026 |
|---|---|---|---|---|
Domestic (Korea) | 68.03 | 70.16 | 69.89 | 73.45 |
Export | 7.28 | 6.88 | 5.90 | 6.35 |
Export share (%) | 9.7 | 8.9 | 7.8 | 8.0 |
Region (KRW Bn) Overview
| Region (KRW Bn) | H1-2026 |
|---|---|
Domestic (Korea) | 37.8 |
Export | 3.0 |
Export share (%) | 7.3 |
Country Overview
| Country | Export value (KRW Mn) | Share (%) |
|---|---|---|
Vietnam | 2,358 | 30.40 |
Philippines | 2,253 | 29.04 |
Thailand | 982 | 12.66 |
Indonesia | 516 | 6.66 |
Uzbekistan | 514 | 6.63 |
Libya | 277 | 3.57 |
Myanmar | 192 | 2.48 |
Japan | 173 | 2.23 |
Mongolia | 102 | 1.32 |
Malaysia | 92 | 1.20 |
Cambodia | 88 | 1.15 |
China | 77 | 1.00 |
Other | 134 | 1.66 |
Total | 7,758 | 100 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | H1-2026 |
|---|---|---|---|---|---|
Year-end / period-end share price (KRW) | 7,065 | 5,388 | 4,263 | 5,510 | 3,180 |
Market capitalization (KRW Bn) | 75.31 | 57.44 | 45.46 | 58.76 | 33.91 |
Price / book (x) | 0.95 | 0.70 | 0.59 | 0.82 | 0.49 |
Valuation Multiples
| Multiple | BCWorld Pharm | Hana Pharm | Myungmoon Pharm |
|---|---|---|---|
P/E (x) | n.m. (ValueLine shows -10.82) | 8.62 | — |
P/B (x) | 0.45 | 0.45 | 0.42 |
EV / Sales TTM (x) | 1.43 | — | — |
EV / EBITDA TTM (x) | 10.0 | — | — |
Dividend yield (%) | about 3.5 | 3.07 | — |
Dividend History
| Fiscal year | Cash DPS (KRW) | Total cash dividend (KRW Bn) | Stock dividend | Notes | Source |
|---|---|---|---|---|---|
FY2024 | 100 | 0.54 | 0.1 share per share (843,856 shares) | Largest shareholder waived cash for the third consecutive year. Yield about 2.5% at decision | [DP-2024-12], [MT-2024-12] |
FY2025 | — | about 0.9 | Paid-in capital rose from KRW 1.94 bn to KRW 2.13 bn between Dec 2025 and Jun 2026, consistent with a further share issuance such as a stock dividend | Decision 11 Dec 2025. Total +71% year on year | [ETFs], [VL] |
Analyst Conclusions
Management guidance and consensus
Formal annual guidance: none issued.
Medium-term ambition: KRW 200 bn revenue by 2028 and a 30% export share [DP-2024-10], [DP-2025-04].
Consensus: none available.
Run-rate indicators: TTM Jun-2026 revenue KRW 80.3 bn, OP KRW 2.8 bn, EBITDA KRW 11.5 bn [VL].
If H2-2026 matches H2-2025, FY2026 revenue would be roughly KRW 84–85 bn. That would be growth of about 11% (analyst arithmetic, not guidance). This is still far below the IR path of KRW 107.2 bn for 2026F.
Bull case
-
ODT annuity. Three launched ODTs in blockbuster molecules, plus five ODT combinations targeting domestic markets of KRW 50–410 bn each (2027–2028), could add meaningful high-price revenue under tiered pricing [IR-2025-12], [DP-2026-04-23].
-
Operating leverage with deleveraging optionality. H1-2026 showed OP up 73% on revenue up 12.5%. Each KRW 10 bn of debt repaid cuts interest by about KRW 0.5 bn. EV/EBITDA of 10x at P/B 0.45x leaves equity torque if net debt falls [DP-2026-08], [VL].
-
Specialty mix shift. Nucynta, the Jext pen, the pediatric sialorrhea product and the iron-deficiency launch build a less price-sensitive specialty layer. A partnered LAI (D010 with an Indian multinational) would validate the platform [IR-2025-12].
Bear case
-
Balance-sheet fragility. OP/interest is below 1x, about 88% of debt is short-term and working capital is negative. Any operating stumble forces dependence on bank rollovers [VL].
-
Credibility gap. Revenue is running about 25–30% below its own 2024 IR path. Pipeline dates slip and LAIs remain preclinical, so the 2028 target appears unachievable organically [IR-2024-10], [IR-2025-12].
-
Margin squeeze. Rising cost ratios, ODT crowding (originator JW and fast followers) and Korean generic price cuts could erode gross profit faster than SG&A can be cut. Minority leakage further dilutes parent earnings [DP-2026-08], [DP-2026-05-04], [VL].
Catalysts and monitorables (next 12 months)
-
Q3 2026 report (expected mid-November 2026): gross-margin trajectory and first Ambaro OD contribution.
-
FY2026 dividend decision (around December 2026) and any update on stock dividends.
-
Refinancing of current borrowings, and any move to term out debt or sell assets.
-
I2102 antifungal injection filing (2026) and G2302/G2402 launches per the Dec 2025 IR.
-
Commercial uptake of the pediatric sialorrhea product and the iron-deficiency launch.
-
Any definitive LAI licensing agreement (D010) or Japan/EU meropenem milestones.
-
Korean drug-pricing reform decisions affecting listed generics.
-
Identities and intent of the substantial-shareholding filers (Apr–Aug 2026). Further succession steps involving BCWorld Healthcare.
Analyst verdict
BCWorld Pharm is a real, operating specialty-generic business with defensible niches. Its narcotic analgesic injections claim category leadership. Its carbapenem plant is dedicated, a structural barrier. And it has built a credible record of first-in-Korea ODT approvals in three high-volume cardiovascular molecules. EBITDA of about KRW 11.5 bn (TTM Jun-2026) and an EBITDA margin near 14% show that the asset base can generate cash.
The equity story, however, is dominated by the capital structure. About KRW 86 bn of interest-bearing debt, roughly 88% of it current, sits against owners' equity of about KRW 70 bn. Interest expense has exceeded operating income in every recent period, and owners' net income has been negative for two consecutive years, worsened by profit attributable to minority holders of the Wonju subsidiary. The market has priced this harshly. The shares trade near 0.45x book value, and the market cap of about KRW 31 bn is barely a quarter of enterprise value.
Management's strategic logic is sound. Formulation differentiation is the rational response to Korea's tiered generic pricing. But delivery has lagged its own roadmap. FY2025 revenue undershot the October 2024 forecast by 17%. Most ODT timelines slipped, and two LAI programs left the pipeline table. The KRW 200 bn 2028 target should be treated as aspirational rather than as guidance.
H1-2026 is the first genuinely encouraging datapoint in two years: double-digit revenue growth, OP up about 73% and near-breakeven net income. Sustaining it requires gross-margin stabilization in H2-2026, steady ODT uptake, and evidence that operating cash flow can retire debt rather than merely service it.
On balance, the profile is a high-risk, deep-value special situation. The upside depends on deleveraging and ODT execution. The downside sensitivities are refinancing, price cuts and competitive erosion of first-mover ODT pricing. Investors should demand balance-sheet repair before crediting the pipeline.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Age | Source |
|---|---|---|---|---|---|---|
Hong Sung-han (홍성한) | CEO / President. Largest shareholder | CEO since 2006 | Development head at Dong-Wha Pharm (1982–1989). Vice President at Aju Pharm (1999–2006) | BS Pharmacy, Seoul National University (1980). MBA, Sogang University (1993). AMP, SNU (2005) | 68 (Nov 2025) | [IR-2024-10], [DP-2025-11b] |
Hong Young-ki (홍영기) | Vice President (promoted 2025). Strategy & Planning head since 2018. Inside director since 2022, re-elected 2025 | Joined 2018 | Samjong KPMG (CPA). Astellas Korea (marketing) | Sogang University. UCLA MBA | Born 1986 | [DP-2025-11], [IR-2024-10] |
Kim Young-mok, PhD | CTO / Director, R&D Institute head | Since 2024 | Yuhan Corp. formulation research. Head of research at Bukwang Pharm | Sungkyunkwan University (Pharmacy). MS SNU. PhD Hanyang University | — | [IR-2024-10] |
Jang Tae-eok | VP, Sales & Marketing head | Since 2019 | Head of sales at Janssen Korea. Sales head at Boryung | Keimyung University (1985) | — | [IR-2024-10] |
Lee Jung-woo | Managing Director, Yeoju production head | Since 2024 | Development head at Kuhnil Pharm. Manufacturing head at Penmix | Chung-Ang University (Pharmacy). Thunderbird MBA | — | [IR-2024-10] |
Kim Joon | VP, Wonju production head (BCWorld Healthcare) | Since 2020 | Biologics reviewer at MFDS. Plant head for Daewoong Nabota | — | — | [IR-2024-10] |
Won Kwang-sam | CFO / Managing Director | Since 2022 | Samil PwC (CPA). Daewoong Pharm accounting. Finance head at AstraZeneca Korea | SNU (Business; Life Chemistry) | — | [IR-2024-10] |
Lee Tae-hyun | Managing Director, Business Development | Since 2022 | Janssen Korea QA. MSD Korea RA. BD head at DKSH Korea | Chung-Ang University (Pharmacy) | — | [IR-2024-10] |
Board & Management Changes
| Date | Change |
|---|---|
| 2024 | Kim Young-mok appointed CTO and R&D head. Lee Jung-woo appointed Yeoju production head |
| 2025 | Hong Young-ki promoted to Vice President and re-elected inside director |
8 Dec 2025 | 1.35m shares gifted by the CEO (1.0m to Hong Young-ki, 0.35m to daughter Hong Hyun-ju) |
Major Shareholders
| Holder | Shares | Stake (%) | As of |
|---|---|---|---|
Hong Sung-han (CEO) | 1,962,375 | 20.6 | Post-gift, Dec 2025 |
Hong Young-ki (VP) | 1,217,223 | 12.5 | Post-gift, Dec 2025 |
Hong Hyun-ju (daughter) | 350000 received in the gift | — | Dec 2025 |
Treasury shares | — | 4.17 | 2,026 |
Minority shareholders (7,992 holders) | — | 54.6 | End-2025 |
Competitive Landscape
Competitors by Segment
| Area | Competitors | Nature of competition | Source / note |
|---|---|---|---|
Anesthesia / narcotics / pain injectables | Hana Pharm (하나제약, KOSPI 293480) | Market leader in anesthesia and narcotics, which were 34% of its Q2-2026 sales. Remimazolam (Byfavo) and EU-GMP lyophilization | [Butler-Hana], [DP-2025-04b] |
Anesthesia / hospital injectables | Myungmoon Pharm (명문제약, KOSPI 017180) | Hospital and anesthesia-oriented Korean mid-cap with high leverage | [Butler-MM], [DP-2025-12-MM] |
Hospital injectables (broad) | Huons (휴온스) | Large Korean injectables and anesthetics player. | Qualitative only |
ODT chronic-disease formulations | GL Pharma (지엘파마, unlisted) | First pregabalin ODT (approved Feb 2026) and first pitavastatin ODT (approved 27 Jul 2026). Named alongside BCWorld as the two ODT leaders | [DP-2026-04-23], [DP-2026-08-04] |
ODT statins | JW Pharmaceutical (JW중외제약) | Originator of Livalo (pitavastatin). Phase 1 IND for its own ODT approved 30 Apr 2026 | [DP-2026-05-04] |
ODT | Pharmavision (파마비젼) | Later-entrant ODT developer | [DP-2026-05-04] |
ODT combinations (rosuvastatin + ezetimibe) | Dongkook Pharm, Unimed and others | Multiple approvals of rosuvastatin/ezetimibe ODTs, with a September launch race | [DP-2026-05-04], [DP-2026-08-04] |
Carbapenem / antibiotic injectables | Domestic generic meropenem makers | — | — |
LAI development (Korea) | Domestic microsphere developers | — | — |
Peer Comparison FY2025
| Metric | BCWorld Pharm | Hana Pharm | Myungmoon Pharm |
|---|---|---|---|
Exchange / ticker | KOSDAQ 200780 | KOSPI 293480 | KOSPI 017180 |
Revenue FY2025 (KRW Bn) | 75.8 | 239.5 | 195.2 |
Revenue growth FY2025 (%) | 1.3 | 6.3 | 4.7 |
Revenue CAGR FY2021–25 (%) | 5.1 | 5.1 | 9.1 |
Operating income FY2025 (KRW Bn) | 2.0 | 25.8 | 6.8 |
Operating margin FY2025 (%) | 2.6 | 10.8 | 3.5 |
Net income FY2025 (KRW Bn) | -3.1 | 8.8 | 1.4 |
Net margin FY2025 (%) | -4.1 | 3.7 | 0.7 |
R&D / revenue (%) | 11.9 | — | — |
Market cap (KRW Bn, latest) | 31.4 | 150.5 | 41.3 |
P/B (x) | 0.45 | 0.45 | 0.42 |
P/E (x) | n.m. (loss) | 8.62 | — |
Dividend yield (%) | about 3.5 | 3.07 | — |
Recent Developments
Guidance revisions: no formal guidance revisions. Pipeline timelines slipped.



